Objective
To develop a Class Ⅲ twin-block magnetic orthopedic appliance (TMOA-Ⅲ) and to investigate the treatment effects of this appliance on skeletal Class Ⅲ malocclusion of mixed dentition and early permanent dentition.
Methods
The sample consisted of 76 Chinese children (42 males and 34 females, mean age 9.1 years) with Class Ⅲ malocclusion caused by maxillary retrognathism, and the subjects were divided into a treatment group and a control group. The treatment group, 38 subjects (21 males and 17 females), were instructed to wear TMOA-Ⅲ for 5-8 months (mean 7.5 months) and the control group, 38 subjects (21 males and 17 females), did not wear any appliance. Cephalometric radiographs were taken and measurement data were used for analysis.
Results
Compared with the control group, patients of the treatment group showed a favorable increase of maxilla length and anterior movement (PNS-A, P<0.001; SNA, A-NPg, P<0.05), and skeletal Class Ⅲ facial profiles improved (UL-EL, NsPgs-HL, Facial convexity, P<0.001; LL-EL P<0.005).
Conclusions
The results indicate that TMOA-Ⅲ is effective for the treatment of Class Ⅲ malocclusion caused by maxillary retrognathism in mixed dentition and early permanent dentition, which provides another choice for the treatment besides the face mask.
Key words:
Magnetic orthodontic appliance; Skeletal class Ⅲ malocclusion; Maxillary retrusion; Cephalometric measurement; Facial convexity
Abstract Background: The potential role of N6-methyladenosine (m6A) in cancer progression has received tremendous attention over the past few years. The aim of this study was to evaluate the effect of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) on the prognosis of patients and its potential role in gastric cancer. Methods: A total of 305 gastric cancer patients with clinical information were identified from the TCGA dataset. Limma package was used to analyze the differential m6A regulators; the Cox regression model was used to determine the risk factor for OS. A 1:1 propensity score matching (PSM) analysis was employed to adjust for the difference in baseline clinicopathological characteristics between the YTHDF2 low and high expression group. The Cox regression analysis was reused to identify the risk factors for overall survival (OS). GO and KEGG analysis were used to explore the potential role and function of YTHDF2 in gastric cancer. Results: Nineteen m6A methylation regulators were expressed in gastric cancer tissues; YTHDF2 was associated with the prognosis of gastric cancer patients. The expression level of YTHDF2, patient age, and tumor stage were independent risk factors for OS. After PSM, YTHDF2 expression led to a relatively better prognosis and stage. Patients in stage IV had a significantly poor prognosis. The expression of YTHDF2 was associated with cancer-related functions and pathways in gastric cancer. Conclusions: The high expression of YTHDF2 can predict a better prognosis of gastric cancer patients. YTHDF2 exerts a critical role in gastric cancer progression.
Objectives: 1) Develop an accurate detection system for head and neck squamous cell carcinoma (HNSCC) using tumor specific nanoparticle‐based probes. 2) Apply these probes for real‐time non‐invasive HNSCC detection using molecular imaging (MI) system. Methods. Fluorescence‐labeled LDS nanoparticles targeting Hsp47 (a highly specific biomarker for HNSCC) were constructed. The HNSCC targeted properties of these constructs were evaluated in vitro using human HNSCC tumor cell lines and in a mouse model of HNSCC with a MI system. Results: Fluorescence‐labeled LDS nanoparticles demonstrated HNSCC tumor cell targeting properties in vitro. Furthermore, this targeting strategy demonstrated accurate and real time tumor detection using MI system. Conclusions: Our study suggests that these novel nanoparticle‐based HNSCC tumor‐targeting constructs have the potential to be used clinically for non‐invasive, accurate, and real time detection of tumors for patients evaluated for HNSCC.
There is limited available data addressing whether inactivated COVID-19 vaccination before conception is associated with adverse neonatal outcomes. This cohort study included all singleton live births at our center from March 1 to June 30, 2022. According to whether a maternal inactivated COVID-19 vaccination had been administered within 3 months before conception or not, neonates were identified as being in the vaccinated or unvaccinated group. Vaccination information and clinical characteristics were extracted for analysis. Furthermore, neonatal outcomes were analyzed and compared between these two groups in the present study. The cohort included 856 eligible newborns, of whom 369 were exposed to maternal vaccination before conception and 487 were unexposed newborns. No differences were observed in rates of preterm birth, newborns being small for gestational age, or neonatal intensive care unit admission between exposed and unexposed newborns. Furthermore, even after adjusting for social–economic status and maternal characteristics, there remained no significant differences in these neonatal outcomes. Our study revealed no statistically significant differences between newborns born to women who received inactivated vaccines prior to conception compared with those who did not receive any vaccinations. In addition, our study also highlights the importance of considering COVID-19 vaccination before conception.
Abstract Recent single-cell RNA sequencing (scRNA-seq) analyses have offered much insight into the gene expression profiles in early-stage kidney development. However, comprehensive gene expression profiles from mid- and late-stage kidney development are lacking. In the present study, by using the scRNA-seq technique, we analyzed 54,704 rat kidney cells from just after birth to adulthood (six time points: postnatal days 0, 2, 5, 10, 20, and 56) including the mid and late stages of kidney development. Twenty-five original clusters and 13 different cell types were identified during these stages. Gene expression in these 13 cell types was mapped, and single cell atlas of the rat kidney from birth to maturity ( http://youngbearlab.com ) was built to enable users to search for a gene of interest and to evaluate its expression in different cells. The variation trend of six major types of kidney cells—intercalated cells of the collecting duct (CD-ICs), principal cells of the collecting duct (CD-PCs), cells of the distal convoluted tubules (DCTs), cells of the loop of Henle (LOH), podocytes (PDs), and cells of the proximal tubules (PTs)—during six postnatal time points was demonstrated. The trajectory of rat kidney development and the order of induction of the six major types of kidney cells from just after birth to maturity were determined. In addition, features of the dynamically changing genes as well as transcription factors during postnatal rat kidney development were identified. The present study provides a resource for achieving a deep understanding of the molecular basis of and regulatory events in the mid and late stages of kidney development.
Preterm birth was previously identified as a high-risk factor for the long-term development of chronic kidney disease. However, the detailed pattern of podocyte (PD) changes caused by preterm birth and the potential mechanism underlying this process have not been well clarified. In present study, a rat model of preterm birth was established by delivery of pups 2 days early and podometric methods were applied to identify the changes in PDs number caused by preterm birth. In addition, single-cell RNA sequencing (scRNA-seq) and subsequent bioinformatic analysis were performed in the preterm rat kidney to explore the possible mechanism caused by preterm birth. As results, when the kidney completely finished nephrogenesis at the age of 3 weeks, a reduction in the total number of differentiated PDs in kidney sections was detected. In addition, 20 distinct clusters and 12 different cell types were identified after scRNA-seq in preterm rats (postnatal day 2) and full-term rats (postnatal day 0). The numbers of PDs and most types of inherent kidney cells were decreased in the preterm birth model. In addition, 177 genes were upregulated while 82 genes were downregulated in the PDs of full-term rats compared with those of preterm rats. Further functional GO analysis revealed that ribosome-related genes were enriched in PDs from full-term rats, and kidney development-related genes were enriched in PDs from preterm rats. Moreover, known PD-specific and PD precursor genes were highly expressed in PDs from preterm rats, and pseudotemporal analysis showed that PDs were present earlier in preterm rats than in full-term rats. In conclusion, the present study showed that preterm birth could cause a reduction in the number of differentiated PDs and accelerate the differentiation of PDs.
Although oxaliplatin (OXA) is widely used in the frontline treatment of colorectal cancer (CRC), CRC recurrence is commonly observed due to OXA resistance. OXA resistance is associated with a number of factors, including abnormal regulation of pyroptosis. It is therefore important to elucidate the abnormal regulatory mechanism underlying pyroptosis. Here, we identified that the circular RNA circPDIA3 played an important role in chemoresistance in CRC. CircPDIA3 could induce chemoresistance in CRC by inhibiting pyroptosis both in vitro and in vivo. Mechanistically, RIP, RNA pull-down and co-IP assays revealed that circPDIA3 directly bonded to the GSDME-C domain, subsequently enhanced the autoinhibitory effect of the GSDME-C domain through blocking the GSDME-C domain palmitoylation by ZDHHC3 and ZDHHC17, thereby restraining pyroptosis. Additionally, it was found that the circPDIA3/miR-449a/XBP1 positive feedback loop increased the expression of circPDIA3 to induce chemoresistance. Furthermore, our clinical data and patient-derived tumor xenograft (PDX) models supported the positive association of circPDIA3 with development of chemoresistance in CRC patients. Taken together, our findings demonstrated that circPDIA3 could promote chemoresistance by amplifying the autoinhibitory effect of the GSDME-C domain through inhibition of the GSDME-C domain palmitoylation in CRC. This study provides novel insights into the mechanism of circRNA in regulating pyroptosis and providing a potential therapeutic target for reversing chemoresistance of CRC.
Abstract The conversion of serine and glycine that is accomplished by serine hydroxymethyltransferase 2 (SHMT2) in mitochondria is significantly upregulated in various cancers to support cancer cell proliferation. In this study, we observed that SHMT2 is acetylated at K95 in colorectal cancer (CRC) cells. SIRT3, the major deacetylase in mitochondria, is responsible for SHMT2 deacetylation. SHMT2-K95-Ac disrupts its functional tetramer structure and inhibits its enzymatic activity. SHMT2-K95-Ac also promotes its degradation via the K63-ubiquitin–lysosome pathway in a glucose-dependent manner. TRIM21 acts as an E3 ubiquitin ligase for SHMT2. SHMT2-K95-Ac decreases CRC cell proliferation and tumor growth in vivo through attenuation of serine consumption and reduction in NADPH levels. Finally, SHMT2-K95-Ac is significantly decreased in human CRC samples and is inversely associated with increased SIRT3 expression, which is correlated with poorer postoperative overall survival. Our study reveals the unknown mechanism of SHMT2 regulation by acetylation which is involved in colorectal carcinogenesis.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)